Who to call at CARTESIAN THERAPEUTICS, INC., and when
Fundz watches for the moments CARTESIAN THERAPEUTICS, INC. starts buying, and tells you who to reach.
- An alert the day CARTESIAN THERAPEUTICS, INC. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at CARTESIAN THERAPEUTICS, INC., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at CARTESIAN THERAPEUTICS, INC.. With Fundz connected, it knows.
CARTESIAN THERAPEUTICS, INC.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
selectabio.com2 executive changes at Selecta Biosciences in the last 90 days. Clusters like this usually mean more senior seats open over the next few months.
See every company with multiple executive changes →AI Executive Summary
AI-powered analysis of 8-K filing content
Cartesian Therapeutics eliminated its Chief Scientific Officer position and terminated Dr. Christopher Jewell without cause, effective November 14, 2025. The separation agreement, signed October 20, 2025, includes a release of claims in exchange for 12 months' salary and a pro-rated bonus eligibility, and the company says the change may affect its research direction.
Key Takeaways
The company eliminated the CSO role entirely rather than filling it, so scientific leadership responsibilities will be redistributed or restructured.
Dr. Jewell's termination is without cause and takes effect November 14, 2025, with the separation agreement executed October 20, 2025.
3 more takeaways
Filing Overview
What This Means
CARTESIAN THERAPEUTICS, INC. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.